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ABSTRACT 
 
Introduction: Burning mouth syndrome (BMS) is a chronic, idiopathic, intraoral mucosal pain condition in 
the absence of specific oral lesions and systemic disease. Among evidence-based pharmacological treat-
ments for this disorder, topical and systemic clonazepam, levosulpiride, selective serotonin reuptake inhib-
itors have been used with partial results. Case: We report a case of a 65-year-old healthy woman with a 3-
year history of oral burning. Clinical and laboratory evaluations allowed us to make a diagnosis of burning 
mouth syndrome. She was treated with duloxetine (DLX) (60 mg PO qd), a selective serotonin, and norepi-
nephrine reuptake inhibitor, obtaining a complete remission of symptoms, evaluated via standardized clin-
ical rating scales (BPRS), and an improvement of her quality of life and level of functioning. Discussion: The 
pathogenesis of BMS still remains unclear. Recently, it has been suggested an underlying neuropathic mech-
anism, demonstrating a dysfunction in the trigeminal nociceptive pathways at peripheral and/or central 
nervous system level. The rationale behind the administration of duloxetine resides in its central mechanism 
of action, and analgesic effects previously demonstrated in diabetic peripheral neuropathy, and fibromyal-
gia. Also, it has been shown to reduce painful physical symptoms associated with depression. Conclusion: 
We hypothesize that duloxetine might represent a useful, effective, and additional therapeutic option in the 
treatment of BMS. 
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INTRODUCTION  
Burning mouth syndrome (BMS) is a chronic idio-
pathic pain condition that affects more than one mil-
lion individuals in the United States[1] The Interna-
tional Association for the Study of the Pain has iden-
tified it as a distinctive nosological entity, character-
ized by a diffuse, continuous burning sensation in-
volving intra-oral soft tissue, lasting at least 4–6 
months, in the absence of specific oral lesions without 
alterations in blood tests and/or instruments find-
ings [2] BMS usually occurs in the fifth-seventh decade 
of life with an estimated prevalence range from 0.7% 
to 4.6% in the general adult population [3] It is more 
common in females than males and was reported in 
1–4% of women attending the centers for menopau-
sal treatment [4] In almost all patients, BMS is charac-
terized by widespread mucosal symptoms (burning, 
pain, dysesthesia, hyperesthesia) involving mainly 
the tongue. Other sites generally affected are the hard 
palate, lips, alveolar ridges, cheek, and floor of the 
mouth. Multiple etiological factors of local, systemic 
and psychological origins have been suggested. Alt-
hough many drugs have been proposed for the treat-
ment of BMS, the management is not yet satisfactory. 
BMS is commonly treated with systemic anxiolitytics, 
antidepressants, and anticonvulsivant drugs. [5, 6] 
Duloxetine (DLX) is a selective dual reuptake inhibi-
tor of serotonin and norepinephrine, which has been 
shown to be efficacious, safe, and well tolerated in the 
treatment of pain and major depressive disorder 
(MDD) in patients with at least moderate pain associ-
ated with depression.[7] 
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Clinical studies have also provided evidence for the 
efficacy of DLX for pain conditions, as diabetic periph-
eral neuropathic pain (DPNP)[8] and fibromyalgia 
with or without major depressive disorder.[9] We re-
port a case of a patient with BMS successfully treated 
with DLX. 
CASE STUDY 
A 65-year-old woman was admitted to our Depart-
ment for a burning sensation localized on her tongue 
and lips, which has lasted for 3 years. Pain was daily 
continuous but improved by meals. She did not report 
any worsening factor associated with burning. Over 
the previous 3 years, the patient saw a general prac-
titioner who made a diagnosis of oral candidiasis and 
prescribed her topical nystatine (oral suspension, 
100,000 units twice a day as mouthwash) and flucon-
azole (100 mg PO q.i.d) for 7 days, without any im-
provement of the symptoms. On admission, body 
temperature was 36.5°C, her heart rate was 72 beats 
per min, and her blood pressure 100/60. The in-
traoral and extra oral clinical examination did not re-
veal any abnormalities and the salivary flow rates 
were normal. Patient was examined by a complete la-
boratory work-up, including complete blood cell 
count, blood urea nitrogen, creatinine, glycemia, glu-
cose tolerance test. All other parameters were within 
normal limits. She denied other medical antecedents 
or use of medications. On physical examination, she 
appeared otherwise healthy. Other symptoms re-
ported were itching ears and chronic fatigue.  
Based on clinical, laboratory and anamnestic data we 
established a diagnosis of BMS. The psychiatric exam-
ination revealed that the patient did not meet DSM-IV 
TR or ICD-10 criteria for any psychiatric disorder and 
had no history of depression, anxiety, or any psychi-
atric diagnosis. Furthermore the patient was negative 
for any psychiatric therapy. She underwent a scale for 
psycho diagnostic evaluation: Hamilton depression 
scale (HAM-D), State-Trait Anxiety Inventory Form Y 
1-2 form (STAY-Y), visual analog scale (VAS), pain nu-
meric rating scale (PNRS). All these tests were per-
formed at baseline after 6 and 12 months except for 
PNRS, which was carried out at baseline, and after 3, 
6, and 12 months. HAM-D scale results did not reveal 
depression (At baseline:4, at 6 months: 7, and at 12 
months: 5; normal range 0–8), STAY-Y scale results 
revealed a very mild anxiety (at baseline: 45, and at 6 
and 12 months: 43; normal range 0–41). At baseline, 
patient started therapy with DLX (60 mg PO qd). After 
3 months of treatment she reported a 40% improve-
ment of pain (a decrease from 9 to 5 on PNRS), and 
then, a tapering of DLX from 60 to 30 mg daily was 
scheduled.  
One month later, patient showed a further improve-
ment (a decrease from 5 to 4 on PNRS) but she re-
ported a moderate constipation as side effect, and 
thus, voluntarily ceased taking DLX. Ten days after 
withdrawal, oral burning symptom increased by 40% 
(from 4 to 8 on PNRS), for which DLX was restarted 
at the dosage of 60 mg daily. Her symptoms reduced 
again by 40% (from 8 to 4 on PNRS) within a month, 
then, by 100% within 6 months (from 4 to 1 on 
PNRS), obtaining a complete remission of symptoms. 
Likewise, her quality of life showed an improvement 
in Sheehan disability scale (SDS) based on 3 parame-
ters work, social life and family life (from 6.33 at 
baseline to 2.66 after 12 months of therapy). A very 
mild constipation reappeared, but did not require any 
medical treatment or immediate discontinuation of 
therapy. DLX was progressively tapered up to its 
complete withdrawal within 30 days. The patient was 
followed-up for 12 months, showing a complete and 
long-lasting clinical remission. 
DISCUSSION 
BMS is a quite common disease which mainly affects 
postmenopausal women and its prevalence in the 
general population ranges from 0.7% to 15%. It is 
characterized by spontaneous oral discomfort or 
burning in the tongue or other mucous membrane 
without organic cause.[10, 11] 
The pathogenesis of BMS still remains poorly under-
stood: both psychological and neuro physiological 
factors have been involved[12] Indeed, a psychiatric 
co-morbidity was reported in many studies, ranging 
from 19% to 85%[3, 4] Other investigations have re-
vealed a variety of psychosocial features and person-
ality disorders in BMS patients, such as alexythymic 
traits, somatization, obsession-compulsion. and so-
cial isolation[5, 6] In addition, a chronic pain can obvi-
ously increase the risk for depression and anxiety 
even in patients with no history of these problems. In 
addition, neurophysiological and imaging studies 
have suggested a dysfunction of the nigrostriatal and 
mesolimbic dopamine pathways in BMS patients sim-
ilar to those found in patients with anxiety and other 
levels of psychological distress. These studies re-
vealed a net brain hypo activity, which should cause 
a loss of function in descending inhibitory sero-
tonergic and noradrenergic pathways, or at least, 
contribute to chronic pain[13] These hypotheses might 
explain the efficacy of serotonin and noradrenalin re-
uptake-blocking antidepressant in BMS, too. Until 
now, the mainstay of treatment for BMS has been an-
tidepressant and benzodiazepines.[5] This is the first 
study reporting on the efficacy of DLX in the treat-
ment of BMS. DLX has been approved by the Food and 
Drug Administration in the United States for the 
treatment of MDD and DPNP in 2004, and more re-
cently in 2008, for fibromyalgia. Notably, it has re-
ceived the same approval in Italy, except for fibrom-
yalgia. DXL is a mixed serotoninnorepinephrine 
reuptake inhibitor and a potent inhibitor of the inac-
tivation by neuronal reuptake of both serotonin and 
norepinephrine with similarly high affinity for their 
transporter proteins (SERT and NET) in brain and 
other tissues.  
The drug has considerably less affinity for the dopa-
mine transporter, and low affinity or for histaminic, 
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adrenergic, cholinergic, serotoninergic, opioid, and 
other receptors. We assumed that the efficacy of DLX 
in treating BMS might be due to its peculiar pattern of 
modulation of serotonin and norepinephrine neuro-
transmission, even in the absence of a diagnosis of de-
pression. Also, DLX showed fast acting, few side ef-
fects with a good tolerability, and long-term results. 
We obtained a complete remission of symptoms 
(PNRS from 9 to; VAS from 8.1 to 1) after 1 year of 
therapy with DLX, with no relapse during the follow-
up. In addition, the treatment with DXT has shown a 
high improvement of her quality of life and indeed, 
her work ability, social life, and family life or home re-
sponsibilities were highly impaired at baseline and 
improved to a total of more than 50% after 12 months 
therapy. 
CONCLUSION 
The present report suggested that DLX, in a benefit 
analysis, might be effective for patients with BMS, 
even without anxiety and depression, due to its effi-
cacy on neuropathic pain but, in order to better con-
firm the observation, should be proved on a larger co-
hort of patients in multi center randomized con-
trolled clinical trials. 
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